Akèy › Kasinòm epitelyal ovè
Etid klinik pou Kasinòm epitelyal ovè ap rekrite nan Etazini
26 etid pou Kasinòm epitelyal ovè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA8 etid
- Durham, NC8 etid
- Chicago, IL7 etid
- San Diego, CA7 etid
- New York City, NY7 etid
- Philadelphia, PA6 etid
- Baltimore, MD6 etid
- Houston, TX6 etid
- Cleveland, OH6 etid
- Edison, NJ5 etid
- Los Angeles, CA5 etid
- Minneapolis, MN5 etid
- Portland, OR5 etid
- Salt Lake City, UT5 etid
- New Haven, CT4 etid
- St. Louis, MO4 etid
- San Antonio, TX4 etid
- Birmingham, AL4 etid
- Seattle, WA4 etid
- Arlington, VA4 etid
- Dallas, TX4 etid
- Queens, NY4 etid
- Rochester, MN3 etid
- Mountain View, CA3 etid
- Oklahoma City, OK3 etid
- Columbus, OH3 etid
- Clifton, NJ3 etid
- Nashville, TN3 etid
- Grand Rapids, MI3 etid
- Sioux Falls, SD3 etid
- New Orleans, LA3 etid
- Billings, MT3 etid
- Washington, DC3 etid
- West Palm Beach, FL3 etid
- Dayton, OH3 etid
- Indianapolis, IN3 etid
- Providence, RI3 etid
- Aurora, CO3 etid
- San Francisco, CA3 etid
- Shreveport, LA3 etid
Pa eta
- Alabama4 etid
- Arizona4 etid
- Colorado4 etid
- Connecticut4 etid
- Florid11 etid
- Georgia3 etid
- Illinois8 etid
- Indiana3 etid
- Kalifòni10 etid
- Lwizyàn4 etid
- Maryland7 etid
- Massachusetts9 etid
- Michigan5 etid
- Minnesota7 etid
- Missouri5 etid
- Montana3 etid
- New Jersey9 etid
- New York10 etid
- North Carolina9 etid
- Ohio10 etid
- Oklahoma3 etid
- Oregon6 etid
- Pennsylvania10 etid
- Rhode Island3 etid
- South Dakota3 etid
- Tennessee6 etid
- Texas12 etid
- Utah5 etid
- Virginia6 etid
- Washington6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT06915025A Study of Isoquercetin in People With Ovarian Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07303894ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Aug 17, 2026 · NCT07764133Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Aug 6, 2026 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jul 1, 2026 · NCT05429970[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Jun 23, 2026 · NCT07432633CT-95 in Advanced Cancers Associated With Mesothelin Expression
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06756035Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou May 19, 2026 · NCT06305299Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 30, 2026 · NCT05297734A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Apr 7, 2026 · NCT04516447A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Ap rekriteEtid obsèvasyon
Laj 30 ak plis · Fanm · Mizajou Sep 16, 2025 · NCT04794322A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2025 · NCT05086692BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 7, 2025 · NCT04196257Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 80 · Fanm · Mizajou Feb 28, 2025 · NCT00005095Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.